Milton Abraham Gómez-Hernández

Mr. Milton Abraham Gómez-Hernández

Departamento de farmacología, Universidad Nacional Autónoma de México, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
K. Eurídice Juárez-MercadoK. Eurídice Juárez-Mercado
K. Eurídice Juárez-Mercado
MGMilton Abraham Gómez-Hernández
Milton Abraham Gómez-Hernández
JSJuana Salinas-Trujano
Juana Salinas-Trujano
Luis Cordova-BahenaLuis Cordova-Bahena
Luis Cordova-Bahena
CEClara Inés Espitia
Clara Inés Espitia
Marco Velasco-VelazquezMarco Velasco-Velazquez
Marco Velasco-Velazquez
SARS-CoV-2 Main Protease (Mpro) is an enzyme that cleaves viral polyproteins translated from the viral genome, which is critical for viral replication. Mpro is a target for anti-SARS-CoV-2 drug development. Herein, we performed a large-scale virtual screening by comparing multiple structural descriptors of reference molecules with reported anti-coronavirus activity against a library with >17 million compounds. Further filtering, performed by applying two machine learning algorithms, identified eighteen computational hits as anti-SARS-CoV-2 compounds with high structural diversity and drug-like properties. The activities of twelve compounds on Mpro’s enzymatic activity were evaluated by fluorescence resonance energy transfer (FRET) assays. Compound 13 (ZINC13878776) significantly inhibited SARS-CoV-2 Mpro activity and was employed as a reference for an experimentally hit expansion. The structural analogues 13a (ZINC4248385), 13b (ZNC13523222), and 13c (ZINC4248365) were tested as Mpro inhibitors, reducing the enzymatic activity of recombinant Mpro with potency as follows: 13c > 13 > 13b > 13a. Then, their anti-SARS-CoV-2 activities were evaluated in plaque reduction assays using Vero CCL81 cells. Subtoxic concentrations of compounds 13a, 13c, and 13b displayed in vitro antiviral activity with IC50 in the mid micromolar range. Compounds 13a–c could become lead compounds for the development of new Mpro inhibitors with improved activity against anti-SARS-CoV-2.

30 January 2021 in Plants
Verified
Journal Article
Open access
PDF file
MGMilton Abraham Gómez-Hernández
Milton Abraham Gómez-Hernández
MFMiriam V. Flores-Merino
Miriam V. Flores-Merino
JSJesús Enrique Sánchez-Flores
Jesús Enrique Sánchez-Flores
Cristina Burrola-AguilarCristina Burrola-Aguilar
Cristina Burrola-Aguilar
CGCarmen Zepeda Gómez
Carmen Zepeda Gómez
María Elena Estrada-ZúñigaMaría Elena Estrada-Zúñiga
María Elena Estrada-Zúñiga
The research on compounds exhibiting photoprotection against ultraviolet radiation (UVR) is a matter of increasing interest. The methanolic extract of a cell culture of Buddleja cordata has potential photoprotective effects as these cells produce phenolic secondary metabolites (SMs). These metabolites are attributed with biological activities capable of counteracting the harmful effects caused by UVR on skin. In the present work, the methanolic extract (310–2500 µg/mL) of B. cordata cell culture showed a photoprotective effect on UVB-irradiated 3T3-Swiss albino fibroblasts with a significant increase in cell viability. The greatest photoprotective effect (75%) of the extract was observed at 2500 µg/mL, which was statistically comparable with that of 250 µg/mL verbascoside, used as positive control. In addition, concentrations of the extract higher than 2500 µg/mL resulted in decreased cell viability (≤83%) after 24 h of exposure. Phytochemical analysis of the extract allowed us to determine that it was characterized by high concentrations of total phenol and total phenolic acid contents (138 ± 4.7 mg gallic acid equivalents and 44.01 ± 1.33 mg verbascoside equivalents per gram of extract, respectively) as well as absorption of UV light (first and second bands peaking at 294 and 330 nm, respectively). Some phenylethanoid glycosides were identified from the extract.

Verified
Journal Article
Open access
PDF file
MGMilton Abraham Gómez-Hernández
Milton Abraham Gómez-Hernández
Adiel Ortega AyalaAdiel Ortega Ayala
Adiel Ortega Ayala
OROSCAR RODRIGUEZ-LIMA
OSCAR RODRIGUEZ-LIMA
APAbraham Landa Piedra
Abraham Landa Piedra
GAGustavo Acosta-Altamirano
Gustavo Acosta-Altamirano
JMJUAN ARCADIO MOLINA-GUARNEROS
JUAN ARCADIO MOLINA-GUARNEROS
Diabetes type 2 (DT2) entails significant health, economic, and productivity repercussions around the world. Poor glycaemic control, defined as an HbA1c >7.0%, has been associated with a number of complications. In spite of the large share of healthcare resources allocated to DT2 treatment, the proportion of controlled Mexican patients is among the lowest in the world (34.4%). Certain protein-encoding genetic polymorphisms involved in metformin transport may affect glycaemic control. We focused on determining the frequency of rs2289669, rs2252281, rs12943590, and rs34834489 polymorphisms in Mexican-Mestizo patients from the Tertiary Care Regional Hospital of Ixtapaluca, State of Mexico, Mexico, as well as assessing their possible association with therapeutic efficacy, as estimated through glycated haemoglobin. The individual polymorphism analysis did not reveal an association with glycaemic control; however, when combined with rs72552763 and rs622342, we found a significant positive correlation between HbA1c levels and metformin dose, which prevailed among patients carrying allelic variants of rs2289669 or rs12943590 who were also simultaneously carrying allelic variants of rs72552763 or rs622342. Patients carrying the reference allele of rs34834489 reported a significant positive correlation between HbA1c levels and metformin dose as well, regardless of their rs72552763 or rs622342 genotype. Thus, we identified alleles and allelic combinations of SLC47A1, SLC47A2, and SLC22A1 polymorphisms posing a potential glycaemic control risk in Mexican-Mestizo patients.